Background Assessing the impact and effectiveness of HPV vaccines on anogenital warts in
the United States can provide early indication of the success of vaccination programs as well …

Background We assessed the effectiveness of the quadrivalent human papillomavirus
vaccine (qHPV) vaccination program in Manitoba, Canada, in reducing incident anogenital …

Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human
papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the …

We examined the effectiveness of human papillomavirus vaccination by dose number and
spacing against incident genital warts in a cohort of 64,517 female health-plan enrollees in …

Anogenital warts (AGWs) rank among the most frequent sexually transmitted infections in
young adults. They are benign lesions, but they pose a significant economic cost to health …

Objectives To assess the effectiveness of the HPV vaccines in preventing genital warts (GW)
in women aged 14–23 years and to estimate the incidence of GW in the whole population …

Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …

In Québec province in Canada, a public school‐based and catch‐up HPV vaccination
programs with the quadrivalent vaccine have been introduced in September 2008 for girls …

Introduction This study aimed to evaluate the early population impact of Ontario's school-
based human papillomavirus (HPV) vaccination program, implemented in September 2007 …

Human papillomavirus (HPV), the most common sexually transmitted infection in the US and
worldwide, can cause cancers, anogenital warts (AGW), and recurrent respiratory …